All News

podcast logo

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.

Read Article
sperm.fertilization.preg_.jpg

Filgotinib Decision Delayed by FDA

Jack Cush, MD

On August 18th, Gilead and Galapagos received a complete response letter from the FDA, which will delay consideration of filgotinib for the treatment of moderate-to-severe RA.

Read Article
ranew.jpg (keep)

Upadacitinib is Superior to Methotrexate in Early RA

Jack Cush, MD

In a head-to-head trial against methotrexate, JAK1 inhibition with upadacitinib was shown to be more effective in early, DMARD-naive RA patients. Here are the primary results.

Read Article
podcast logo

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

Jack Cush, MD

Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.

Read Article
COVID infection mask

Rheumatic Diseases, Drugs and COVID-19 Guidelines

Jack Cush, MD

Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.

Read Article
infusion.biologic.jpg

Infliximab Use Near Surgery is Safe

Jack Cush, MD

Risk factors for perioperative infections include age, comorbidity, rheumatoid arthritis and steroids to name a few; whether concurrent use of TNF inhibitor (TNFI) therapy adds to this risk has been debated. In a study of elderly patients receiving infliximab infusions, infliximab use prior to surgery did not change the risk of post-operative infections.

Read Article
hospital.ER_.jpg (keep)

DMARD Use Does Not Increase COVID Hospitalization

Jack Cush, MD

An observational study of patients with systemic autoimmune inflammatory rheumatic diseases (AIRD) who also had COVID-19 disease shows that AIRD increased the risk of hospitalization, but that the use of disease-modifying antirheumatic drugs (DMARDs) were not associated with hospitalization.

Read Article
LBP.red_.jpg

Secukinumab Effective in Non-Radiographic Axial SpA

Jack Cush, MD

The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.

Read Article
Xeljanz4.jpg

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Jack Cush, MD

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  

Read Article
podcast logo

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jack Cush, MD

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
podcast logo

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
Responses to switching TNFi in SpA go down w/ the 2nd TNFi. 1st TNFi @ 3 mos ASAS CII 51%; 2nd TNFi 41%; BASDAI @6 mo, 1st 46%, 2nd TNFi 33%. Compared to primary failure, pts w/ 2nd failure (OR 7.3 ) or toxicity (OR 9.1) had better ASDAS-I https://t.co/jMCUfBtxmY https://t.co/PBkQNOwVRQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Telemedicine: What's Changed and What Needs to be Addressed? An update on legislative changes, uncertainties, and the care gap post COVID https://t.co/HRAsEP7IL6 https://t.co/X6PL0W4tI7

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 2 Canadian centers finds amongst 2095 patients taking biologics for #Psoriasis, 23 (1.1%) stopped their biologic for "COVID-19 related concerns". 5/23 restarted biologic for PSO flares. This included TNFi, inhibitors of IL17, IL12/23, IL23 https://t.co/gjSX4P0LMK

Links:

Dr. John Cush RheumNow ( View Tweet)

BMS has announced deucravacitinib: the generic name for its Tyk2 inhibitor (BMS-986165) - 15 long makes it a new rheum labeling record. It's being studied in Psoriatic arthritis, psoriasis, lupus and inflammatory bowel disease. https://t.co/E2x2lelktO

Links:

Dr. John Cush RheumNow ( View Tweet)

RA is associated with a 24‐35% lower risk of type 2 diabetes. Claims data comparison of 449,327 RA, general non‐RA, hypertension, OA, or PsA patients finds a lower risk of T2DM in RA (7/1000PY) and highest w/ HTN (12.3/1000PY) https://t.co/uZn5qaImO9

Links:

Dr. John Cush RheumNow ( View Tweet)

Full read clinical practice guideline on obesity management from the Canadian Medical Assn Journal. https://t.co/YdbjtnBcST

Links:

Dr. John Cush RheumNow ( View Tweet)

EU has approved Secukinumab (Cosentyx) for use in pediatric plaque psoriasis - moderate-to-severe psoriasis affects more than 350,000 children worldwide. Approval is based on 2 phase 2 wo international in children 6 to <18 years. https://t.co/Y05ElRr6xn

Links:

Dr. John Cush RheumNow ( View Tweet)

Virtual Video Joint Exam Pearl #5: Its easier to see gouty Tophi and rheumatoid nodules than nail changes of PsA or subtle rashes. For Rashes and oral lesions its BEST to have the patient take multiple pix with the cell phone and send them in by EMR or Email.

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - COVID-19 Responds to Steroids & TCZ, statin myopathy, Lung Dz in AOSD, TNFi & Liver, IL-23 in Psoriasis. Watch it here>> https://t.co/DrrFZSWmZa or listen to Podcast on iTunes>> https://t.co/FHJv01AAbC or on SoundCloud>> https://t.co/nSPI9lcaY9

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×